A Position Paper on Lipoprotein(a) From the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis: Current Evidence, Clinical Applications, and Future Directions

Author's summary Elevated lipoprotein(a) (Lp[a]) is increasingly recognized as an independent cardiovascular risk factor, yet awareness, standardized measurement, and treatment strategies remain limited in Korea. This position paper from the Lipoprotein(a) Task Force of the Korean Society of Lipid and Atherosclerosis highlights unmet needs in screening, summarizes Korean epidemiologic and clinical evidence, and reviews current and emerging therapies. By contextualizing global advances within the Korean healthcare system, this work provides guidance for clinicians and underscores the need for future research and therapeutic development to reduce the burden of Lp(a)-related cardiovascular disease.

• Publication year

  2025

• Venue

  Korean Circulation Journal

• Publication date

  2025-12-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.4070/kcj.2025.0388PMID 41560299PMCID 12834630
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Viewpoint on the 2025 Focused Update of the 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2025cited by this paper
• Dyslipidemia Fact Sheet in South Korea, 2024

  2025cited by this paper
• The '10 commandments' for the 2025 focused update of the 2019 ESC/EAS guidelines for the management of dyslipidaemias.

  2025cited by this paper
• Addressing Cardiovascular Diseases Challenges in South Korea: Strategies to Improve Outcomes

  2025cited by this paper
• Design and rationale of Lp(a)HORIZON trial: Assessing the effect of Lipoprotein(a) lowering with Pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a).

  2025cited by this paper
• Lepodisiran - A Long-Duration Small Interfering RNA Targeting Lipoprotein(a).

  2025cited by this paper
• Association of lipoprotein(a) and coronary artery calcium with atherosclerotic cardiovascular disease.

  2025cited by this paper
• Prevalence of Elevated Lipoprotein(a) and its Association With Subclinical Atherosclerosis in 2.9 Million Chinese Adults.

  2025cited by this paper
• 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.

  2025cited by this paper
• Consensus on lipoprotein(a) of the Spanish Society of Arteriosclerosis. Literature review and recommendations for clinical practice.

  2024cited by this paper
• A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice.

  2024influential reference
• Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels

  2024cited by this paper
• Lipoprotein(a), C-Reactive Protein, and Cardiovascular Risk in Primary and Secondary Prevention Populations.

  2024cited by this paper
• Intraindividual Variability in Serial Lipoprotein(a) Concentrations Among Placebo-Treated Patients in the OCEAN(a)-DOSE Trial.

  2024cited by this paper
• Zerlasiran-A Small-Interfering RNA Targeting Lipoprotein(a): A Phase 2 Randomized Clinical Trial.

  2024cited by this paper
• Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical Trial.

  2024cited by this paper
• Intra-individual Variability in Lipoprotein(a) Levels: Findings from a Large Academic Health System Population.

  2024cited by this paper
• Association of Lipoprotein(a) With Severe Degenerative Aortic Valve Stenosis

  2024influential reference
• Lipoprotein(a) and Calcific Aortic Valve Stenosis Progression: A Systematic Review and Meta-Analysis.

  2024cited by this paper
• Lipoprotein(a), Oxidized Phospholipids, and Progression to Symptomatic Heart Failure: The CASABLANCA Study

  2024cited by this paper
• Association of lipoprotein(a) with progression of coronary artery calcification: retrospective longitudinal study

  2024influential reference
• Remnant cholesterol in the era of intensive lipid-lowering therapies.

  2023cited by this paper
• Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2022

  2023cited by this paper
• Efficacy and Safety of Inclisiran in Asian Patients

  2023cited by this paper
• Lepodisiran, an Extended-Duration Short Interfering RNA Targeting Lipoprotein(a): A Randomized Dose-Ascending Clinical Trial.

  2023cited by this paper
• Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations.

  2023cited by this paper
• Association of free-living diet composition with plasma lipoprotein(a) levels in healthy adults

  2023cited by this paper
• 2023 Chinese guideline for lipid management

  2023cited by this paper
• Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation: A Randomized Clinical Trial.

  2023cited by this paper
• Consensus document on Lipoprotein(a) from the Italian Society for the Study of Atherosclerosis (SISA).

  2023cited by this paper
• Baseline Lipoprotein(a) Levels and Long-Term Cardiovascular Outcomes After Acute Myocardial Infarction

  2023influential reference
• Mendelian Randomization: Principles and its usage in Lp(a) research.

  2022cited by this paper
• Lipoprotein(a) and Cardiovascular Disease in Chinese Population

  2022cited by this paper
• Lipoprotein(a)-related cardiovascular and all-cause mortalities in Korean adults.

  2022influential reference
• Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.

  2022cited by this paper
• Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

  2022cited by this paper
• Lipoprotein(a) in the Korean Pediatric Population Visiting Local Clinics and Hospitals

  2022cited by this paper
• Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene

  2022cited by this paper
• Beyond fibrinolysis: The confounding role of Lp(a) in thrombosis.

  2022cited by this paper
• Lipoprotein(a) and ethnicities.

  2022cited by this paper
• Non-genetic influences on lipoprotein(a) concentrations

  2022cited by this paper
• Lipoprotein(a): An underestimated inflammatory mastermind.

  2022cited by this paper
• The effect of LPA Thr3888Pro on lipoprotein(a) and coronary artery disease is modified by the LPA KIV-2 variant 4925G>A

  2022cited by this paper
• Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels.

  2022cited by this paper
• Lipoprotein(a), a Lethal Player in Calcific Aortic Valve Disease

  2022cited by this paper
• Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis

  2022cited by this paper
• Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association.

  2022cited by this paper
• Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study

  2021influential reference
• OUP accepted manuscript

  2021cited by this paper
• Lipoprotein(a) and subclinical coronary atherosclerosis in asymptomatic individuals.

  2021influential reference
• Effects of a low-carbohydrate diet on insulin-resistant dyslipoproteinemia—a randomized controlled feeding trial

  2021cited by this paper
• Statin therapy and lipoprotein(a) levels: a systematic review and meta-analysis.

  2021cited by this paper
• Association of Lipoprotein(a) With Recurrent Ischemic Events Following Percutaneous Coronary Intervention.

  2021influential reference
• Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease

  2021cited by this paper
• Associations of Genetically Predicted Lp(a) (Lipoprotein [a]) Levels With Cardiovascular Traits in Individuals of European and African Ancestry

  2021cited by this paper
• 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult.

  2021cited by this paper
• Familial Hypercholesterolemia and Lipoprotein(a): Unraveling the Knot That Binds Them.

  2020cited by this paper
• Lipoprotein(a) and Cardiovascular Diseases　- Revisited.

  2020cited by this paper
• The association between lipoprotein (a) and carotid atherosclerosis in patients with type 2 diabetes without pre-existing cardiovascular disease: A cross-sectional study.

  2020influential reference
• Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease

  2020cited by this paper
• ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk

  2020cited by this paper
• Ascertainment Bias in the Association Between Elevated Lipoprotein(a) and Familial Hypercholesterolemia.

  2020cited by this paper
• Lp(a): When and how to measure it

  2020cited by this paper
• Treatment of Thyroid Dysfunction and Serum Lipids: A Systematic Review and Meta-Analysis.

  2020cited by this paper
• Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome.

  2020cited by this paper
• Lipoprotein(a) Reduction in Persons with Cardiovascular Disease.

  2020cited by this paper
• Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation

  2020cited by this paper
• Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.

  2020cited by this paper
• HEART UK consensus statement on Lipoprotein(a): A call to action.

  2019cited by this paper
• Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups

  2019cited by this paper
• Lipoprotein(a) catabolism: a case of multiple receptors.

  2019cited by this paper
• 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease.

  2019cited by this paper
• Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis.

  2019cited by this paper
• Prevalence of elevated lipoprotein(a) levels in Korean: A large population-based study

  2019cited by this paper
• Lp(a) (Lipoprotein[a])-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.

  2019cited by this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cited by this paper
• Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting

  2018cited by this paper
• Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

  2018cited by this paper
• Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials.

  2018cited by this paper
• Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis

  2018cited by this paper
• Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis

  2017cited by this paper
• Lipoprotein(a) Induces Human Aortic Valve Interstitial Cell Calcification

  2017cited by this paper
• A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.

  2017cited by this paper
• LPA Gene, Ethnicity, and Cardiovascular Events

  2017influential reference
• Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study

  2017cited by this paper
• Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population.

  2016cited by this paper
• Structure, function, and genetics of lipoprotein (a)

  2016cited by this paper
• Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels.

  2016cited by this paper
• Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease

  2016cited by this paper
• Lipoprotein (a) measurements for clinical application

  2016cited by this paper
• Lipoprotein (a): impact by ethnicity and environmental and medical conditions

  2016cited by this paper
• Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans

  2016cited by this paper
• Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

  2016cited by this paper
• Elevated lipoprotein(a) levels predict cardiovascular disease in type 2 diabetes mellitus: a 10-year prospective cohort study

  2016cited by this paper
• Reductions in serum levels of LDL cholesterol, apolipoprotein B, triglycerides and lipoprotein(a) in hypercholesterolaemic patients treated with the liver‐selective thyroid hormone receptor agonist eprotirome

  2015cited by this paper
• Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk Assessment: The Multi-Ethnic Study of Atherosclerosis

  2015cited by this paper
• Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial.

  2015cited by this paper
• Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve

  2015cited by this paper
• Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.

  2015cited by this paper
• Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia: Results of 4 Phase III Trials

  2015cited by this paper

• No citing papers are available for this paper.